Treace Medical Concepts (TMCI) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $45.1 million, up 11% year-over-year, driven by adoption of new technologies, commercial execution, and increased surgeon activity.

• Net loss for Q3 2024 was $15.4 million ($0.25 per share), improved from $17.5 million ($0.28 per share) in Q3 2023.

• Launched Nanoplasty 3D MIS system, entering the large metatarsal osteotomy market and expanding the product portfolio.

• Continued to broaden surgeon customer base and increase procedure volumes with new product introductions.

• Expanded patent portfolio and filed suit to protect Lapiplasty technology.

Financial highlights

• Gross margin was 80.1%, nearly flat compared to 80.4% in Q3 2023 and 80.2% in Q2 2024.

• Operating expenses were $51.3 million in Q3 2024, up from $50.6 million in Q3 2023, reflecting investments in innovation and share-based compensation.

• Adjusted EBITDA loss was $5.1 million, a 45% improvement year-over-year and 42% sequentially.

• Cash, cash equivalents, and marketable securities totaled $82.8 million as of September 30, 2024.

• Long-term debt was $54.0 million as of September 30, 2024.

Outlook and guidance

• Full-year 2024 revenue guidance revised to $204–$211 million, representing 9%–13% growth over 2023.

• Adjusted EBITDA loss expected to decrease by approximately 50% versus full-year 2023.

• Targeting Adjusted EBITDA break-even in 2025, with most improvement expected in the fourth quarter.

• Management expects macroeconomic challenges, including inflation and competition, to continue impacting results.

• Existing cash, marketable securities, available debt, and expected revenues are believed sufficient to fund operations for at least 12 months.